Page 57 - Priority Review News Today

STOCKHOLM, May 22, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...

Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to isaralgagene civaparvovec, or ST-920, a... | May 22, 2023

BOSTON and LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...

/PRNewswire/ -- BioArctic ABs (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that they have submitted a Marketing Authorisation Application...

STOCKHOLM, May 22, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...

Beremagene geperpavec completely closed severe blistering and wounds in more than half of all patients with dystrophic epidermolysis bullosa with specific mutations.

The U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older

/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known...

FDA approves Vyjuvek, a herpes-simplex virus type 1 vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain gene.

SHANGHAI, China and CAMBRIDGE, Mass., May 18, 2023 -- Zai Lab Limited today announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted... | May 18, 2023